Biomarkers Of Immunotherapy In Glioblastoma

IF 2.4 Q2 CLINICAL NEUROLOGY

Neuro-oncology practice Pub Date : 2024-04-01 DOI:10.1093/nop/npae028

William M Savage, Mitchell D Yeary, Anthony J Tang, Colin P. Sperring, Michael G. Argenziano, Arjun R Adapa, Nina Yoh, P. Canoll, Jeffrey N. Bruce

引用次数: 0

Abstract

Glioblastoma (GBM) is the most common primary brain cancer, comprising half of all malignant brain tumors. Patients with GBM have a poor prognosis, with a median survival of 14-15 months. Current therapies for GBM, including chemotherapy, radiotherapy, and surgical resection, remain inadequate. Novel therapies are required to extend patient survival. Although immunotherapy has shown promise in other cancers, including melanoma and non-small lung cancer, its efficacy in GBM has been limited to subsets of patients. Identifying biomarkers of immunotherapy response in GBM could help stratify patients, identify new therapeutic targets, and develop more effective treatments. This article reviews existing and emerging biomarkers of clinical response to immunotherapy in GBM. The scope of this review includes immune checkpoint inhibitor and antitumoral vaccination approaches, summarizing the variety of molecular, cellular, and computational methodologies that have been explored in the setting of anti-GBM immunotherapies.

查看原文本刊更多论文

胶质母细胞瘤免疫疗法的生物标志物

胶质母细胞瘤（GBM）是最常见的原发性脑癌，占所有恶性脑肿瘤的一半。GBM 患者预后较差，中位生存期为 14-15 个月。目前针对 GBM 的疗法，包括化疗、放疗和手术切除，仍然不够完善。需要新的疗法来延长患者的生存期。虽然免疫疗法在其他癌症（包括黑色素瘤和非小肺癌）中显示出良好的疗效，但其在 GBM 中的疗效仅限于部分患者。确定 GBM 免疫疗法反应的生物标志物有助于对患者进行分层、确定新的治疗靶点并开发更有效的治疗方法。本文回顾了现有的和新出现的 GBM 免疫疗法临床反应生物标志物。本综述的范围包括免疫检查点抑制剂和抗肿瘤疫苗接种方法，总结了在抗 GBM 免疫疗法中探索的各种分子、细胞和计算方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuro-oncology practice CLINICAL NEUROLOGY-

CiteScore

5.30

自引率

11.10%

发文量

期刊介绍： Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving